National Bank of Canada
ORKA

National Bank of Canada’s Oruka Therapeutics ORKA Stock Holding History

National Bank of Canada’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8
Closed -$153 – 3194
2025
Q3 		$153 Hold
8
– – ﹤0.01% 2752
2025
Q2 		$89 Hold
8
– – ﹤0.01% 2871
2025
Q1 		$82 Hold
8
– – ﹤0.01% 2724
2024
Q4 		$155 Buy
+8
New +$195 ﹤0.01% 2773

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

National Bank of Canada's ORKA Position: Q4 2025 in Review

National Bank of Canada sold out of Oruka Therapeutics (ORKA) in Q4 2025, closing a stake of 8 shares — an estimated $153 sold.

National Bank of Canada first reported a position in ORKA in Q4 2024 and held it in 4 quarters. The position peaked at $155 in Q4 2024. 143 funds tracked by Wall St. Rank hold ORKA as of Q4 2025.

  • National Bank of Canada reported no remaining Oruka Therapeutics position as of Q4 2025 after selling out during the quarter.
  • National Bank of Canada sold 8 Oruka Therapeutics shares in Q4 2025, an estimated $153.
  • National Bank of Canada first reported a position in Oruka Therapeutics in Q4 2024 and held it in 4 quarters.
  • National Bank of Canada's Oruka Therapeutics position peaked at $155 in Q4 2024.
  • 143 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2025.

Based on National Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.